The FDA’s decision to formally reassess butylated hydroxytoluene (BHT) and azodicarbonamide (ADA) marks one of the agency’s clearest attempts to revisit long-standing food additive approvals through a modernized post-market review framework. The May 2026 announcement did not ban either ingredient. Instead, the agency launched Requests for Information and opened a scientific reassessment process focused on updated exposure data, toxicology research, manufacturing uses, and current market prevalence.
The development carries broader consequences for food and beverage brands because the agency selected two additives that have already become consumer-facing targets in labeling disputes, ingredient transparency campaigns, and retailer reformulation pressure. BHT remains widely used as a preservative in cereals, frozen foods, snacks, and packaged products, while ADA has largely disappeared from major commercial bakery portfolios after years of public scrutiny tied to “yoga mat chemical” marketing narratives. The FDA’s action therefore reaches beyond ingredient safety alone. It raises questions about how legacy GRAS determinations, historical ingredient approvals, and modern consumer perception standards will interact over the next phase of food additive enforcement.
FDA’s Post-Market Food Chemical Review Program Expands Exposure for Legacy Ingredients
The FDA framed the reassessment as part of its finalized post-market chemical safety review program, a framework designed to reevaluate previously approved food substances when new scientific data, international regulatory actions, or exposure concerns emerge. The agency stated that it will use a prioritization process that considers public health signals, scientific literature, changes in consumption patterns, and stakeholder submissions when deciding which chemicals warrant deeper review.
That procedural shift matters because many food additives currently in the market entered commerce decades ago under scientific standards that differ from today’s toxicological methodologies and cumulative exposure models. The FDA has historically faced criticism over the structure of the GRAS system, particularly because companies may self-affirm that certain substances are “generally recognized as safe” without mandatory premarket FDA approval. Consumer advocacy groups and state lawmakers have increasingly argued that the framework leaves too many legacy additives insulated from periodic reassessment.
BHT and ADA therefore function as test cases for how aggressively the agency intends to revisit existing approvals. ADA already carries international regulatory tension because the European Union prohibited its use in foods years ago, while U.S. commercial bakers have voluntarily reduced or eliminated it from many formulations. BHT presents a different challenge because it remains broadly embedded across packaged food categories and continues to serve important shelf-life stabilization functions. If the FDA ultimately questions permissible exposure thresholds or safety assumptions, reformulation costs could spread across multiple consumer packaged goods sectors simultaneously.
Consumer Perception and False Advertising Risk May Outpace FDA Enforcement
One overlooked legal issue involves the widening gap between FDA authorization and consumer-facing marketing exposure. Even where an ingredient remains lawful under federal food additive rules, plaintiffs increasingly frame litigation around consumer perception rather than technical ingredient legality. That distinction has become especially relevant in food labeling cases involving preservatives, synthetic additives, and “clean label” positioning.
For brands using BHT, the legal risk may emerge less from immediate FDA enforcement and more from advertising liability tied to ingredient messaging. Plaintiffs frequently argue that front-label claims implying naturalness, wholesomeness, or ingredient simplicity conflict with the inclusion of synthetic preservatives. Courts evaluating those disputes often focus on reasonable consumer interpretation under state unfair competition statutes rather than on whether the ingredient itself remains federally approved.
ADA presents a related reputational issue because prior media campaigns already transformed the ingredient into a consumer-recognizable controversy. Even without a federal restriction, companies continuing to use ADA may face retailer scrutiny, class action attention, or social media-driven reformulation pressure. The FDA’s reassessment could intensify that exposure by renewing public discussion around additives that many consumers assumed had already disappeared from the food supply.
This creates a legal gap that many companies underestimate: federal permissibility does not eliminate state-law advertising exposure. A lawful additive may still become the basis for allegations involving deceptive marketing, omitted disclosures, or implied health messaging. California consumer protection statutes remain especially active in this area because plaintiffs frequently challenge how ingredient representations influence purchasing decisions regardless of FDA authorization status.
Reformulation Pressure May Reshape Ingredient Portfolio Management
The FDA’s reassessment process may also alter how food manufacturers approach ingredient portfolio management and supplier documentation. Companies that previously treated legacy additives as stable regulatory assets may now need updated toxicological support, enhanced supplier certifications, and more detailed internal substantiation records.
The operational implications extend beyond ingredient removal. Reformulation often affects:
- shelf life stability,
- flavor consistency,
- manufacturing tolerances,
- retailer specifications,
- and comparative advertising claims.
When companies replace preservatives or dough conditioners, they frequently revise packaging claims simultaneously. Those label revisions can create new exposure involving “clean label,” “free from,” or ingredient transparency representations. Competitors may also monitor reformulated products more aggressively under Lanham Act false advertising theories if comparative marketing suggests superior safety or ingredient quality without adequate substantiation.
The FDA’s emphasis on post-market review additionally increases the likelihood that multinational brands will face fragmented standards across jurisdictions. Many global manufacturers already formulate products differently for European and U.S. markets because additive restrictions vary internationally. Expanded FDA reassessments may accelerate pressure toward harmonized global formulations, particularly where retailers or institutional buyers seek ingredient consistency across regions.
The Juris Law Group Perspective on Food Labeling and Advertising Liability
As food and beverage attorneys in California, our practice often involves reviewing how ingredient disclosures, packaging language, and consumer-facing claims interact when regulators revisit long-approved additives. FDA authorization may establish market legality, but it does not eliminate exposure tied to implied product messaging, retailer standards, or consumer interpretation of synthetic ingredients.
Additive reformulation also tends to affect broader brand management decisions beyond ingredient selection alone. Changes involving preservatives or processing agents frequently require parallel review of advertising substantiation, comparative claims, packaging updates, and trademark positioning, particularly where brands market products around transparency, ingredient simplicity, or “clean label” themes.
FDA Reassessment Activity May Expand Beyond BHT and ADA
The next 12 months will likely determine whether the FDA intends to use this framework selectively or as the foundation for recurring additive reassessment campaigns. Consumer advocates are already pressing for closer review of artificial colors, emulsifiers, preservatives, titanium dioxide, and other synthetic ingredients associated with ultra-processed food debates. If the agency prioritizes additional additives for post-market review, manufacturers may face overlapping pressure from federal scrutiny, state legislation, retailer policies, and class action litigation.
The food industry may also see renewed debate around GRAS reform itself. Critics continue to challenge the self-affirmation structure that permits certain ingredients to enter commerce without mandatory FDA notification. Although Congress has not yet advanced major GRAS legislation, the FDA’s current reassessment initiative could increase political momentum for expanded reporting obligations, greater transparency requirements, or more formalized periodic safety reviews.
For brands, the practical consequence is that legacy ingredient approvals no longer appear insulated from modern reassessment. Companies using long-authorized additives may need to evaluate whether continued reliance creates disproportionate litigation exposure, retailer friction, or reputational pressure relative to available alternatives. The FDA’s review of BHT and ADA may ultimately matter less because of the final scientific conclusions and more because it establishes a repeatable mechanism for reopening additive scrutiny across the broader packaged food category.
Common Legal Inquiries
Can a company still use BHT or ADA while the FDA reassessment is pending?
Yes. The FDA has not prohibited either ingredient, revoked approvals, or imposed new restrictions. Companies may continue using permitted substances within existing regulatory parameters while the reassessment process proceeds. Businesses should still evaluate labeling exposure and retailer requirements because litigation risk can develop independently from FDA enforcement.
Does FDA approval prevent false advertising lawsuits involving additives?
No. Plaintiffs frequently challenge ingredient-related marketing under state consumer protection laws even where the ingredient itself remains lawful. Courts often evaluate whether packaging, advertising, or implied messaging could mislead a reasonable consumer about ingredient quality, synthetic content, or product composition.
Could the FDA reassessment process affect other food additives?
Potentially. The agency’s new post-market review framework creates a pathway for future reassessment of additional preservatives, artificial colors, emulsifiers, and other food chemicals. Companies using legacy additives may face increased requests for substantiation, reformulation pressure, or renewed public scrutiny if the FDA expands its review priorities.
